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Abstract  
Malaria, one of the problems in many developing countries is caused by the  protozoan parasite called 
Plasmodium and several cases of the disease are reported annually.  
The emergence of multi-drug resistant malarial parasites necessitates the exploration of novel and promising 
antimalarial enzyme drug target called Plasmodium falciparum histone deacetylase 1 (PfHDAC-1). Thus, in 
this study, a ligand refined homology model of PfHDAC-1 was generated from the crystal structures of 
human HDAC8 and HDLP using a restraint guided optimization procedure involving the OPLS/GBSA 
potential setup. The model was validated using protein structure validation tools. A predictive docking study 
was carried out using nine sets of known HDAC inhibitors, which have been shown experimentally to have 
in vitro antimalarial activity against a strain of P. falciparum. Pose validation and score-based active and 
inactive separation studies provided independent validation of the geometric accuracy and the predictive 
ability of the generated model. Stereo chemical evaluation using Ramachandran plot revealed that 96.5% 
residues of the constructed model lie in the most favored and allowed regions, thus, suggesting a good 
quality model. Comparative analysis was carried out with the human HDAC 8 to ascertain the degree of 
selectivity of the inhibitors for both models. This revealed that YC-II-88 inhibitor was most selective for 
PfHDAC-1 model and showed no inhibitory activity for the human HDAC8 model. 
 Keywords Homology modeling; Plasmodium falciparum; Histone deacetylase; Docking;    
                   Inhibitor 
 
1. Introduction 
Malaria being a mosquito-borne infectious disease caused by protozoan parasites (Plasmodium) is widely 
spread in tropical and subtropical regions of the world. Approximately 500 million clinical cases of malaria 
are reported each year, of which 1-2 million result in death. 90% of the deaths occur in sub-Saharan Africa 
and most are children under the age of five. 50 million of the reported cases are pregnant women. Malaria in 
pregnancy contributes to nearly 20% low birth weight babies and also causes stillbirth and maternal deaths
1-3
. 
There are four known species of the Plasmodium that infect humans. These include P. falciparum, P. vivax, P. 
malariae and P. oval. Unfortunately, P. falciparum causes most of the severity and deaths attributed to the 
disease. They have become increasingly resistant to the currently used drugs; even the Artemisinin based 
Combination Therapies (ACTs) 
4
. Due to this fact, development of drugs attacking crucial targets in the 
metabolism or mechanism of action of the malaria pathogen is imperative.  
The histone deacetylases (HDACs) of P. falciparum are tipped as potential targets for new classes of 
antimalarial drugs.  Histones are highly alkaline proteins found in eukaryotic cell nuclei and play a role in 
gene regulation. A number of HDAC are present in humans and can be classified into four categories
5
 class I 
(HDAC 1,2,3,8), class II (HDAC 4,5,6,7,9,10), class III (Sirtuins), class IV (HDAC 11). The HDACS from 
classes I, II and IV exhibit zinc dependent mechanisms while the Sirtuins which are NAD
+
 dependent 
demonstrates ADP-ribosyltransferase activity in addition to deacetylase activity
6
.  
HDAC inhibitors interfere with the functions of HDAC by arresting cell growth, inducing differentiation as 
well as apoptotic cell death. Generally, inhibitors show little selectivity for plasmodium cells compared with 
their selectivity for human cells
8
. For an outstanding success in the discovery of new and potent drugs, 
emphasis must be laid on the use of inhibitors that are selective towards the plasmodium cells even at very 
low concentrations. This paper therefore presents the homology model of PfHDAC1 and compares the 
results obtained from docking of selected inhibitors on PfHDAC 1 and human HDAC 8 models to that 
obtained experimentally (using the same inhibitors) as reported by Agbor-Enoh et al
8
.  
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2. Materials And Methods  
2.1 Computational Resources  
 All the computational studies were done on an Ubuntu 10.10 (Maverick Meerkat) Linux desktop. Sequence 
alignment, homology modeling, loop and side chain refinement were carried out using Prime version 2.1 
(Schrodinger LLC, New York, NY, 2009). Molecular dynamics was carried out in Desmond version 2.2, 
while Epik and MacroModel versions 2.0 and 9.7 respectively were used for the preparation of the ligands 
before docking
9
. Glide version 5.5 was used for the receptor grid generation and for the docking calculations. 
Maestro version 9.0, which is a graphic unified interphase, was also used to generate figures
9
.  
2.2 Sequence Alignment and Model Building   
The protein sequence of PfHDAC1 was downloaded from the Uniprot server
10
. The crystal structures 1C3R 
(PDB code) from HDLP; a HDAC homologue from A. aeolicus bacterium with 32% sequence identity and 
human HDAC8 (1T64 PDB code) 41% sequence identity were templates used for the building of the model. 
Within Prime, the target sequence was imported in the FASTA format while the templates were imported into 
Maestro and prepared with the Protein Preparation Wizard. Their sequences were extracted and aligned with 
the target sequence using the default alignment procedure of Prime applying BLOSUM62 similarity matrix. 
The HDLP template was used for modeling residues 5 – 26 of PfHDAC1 while residues 27 – 377 were built 
from HDAC8 template. This was possible through the Set Template Regions functionality. The ligand and 
the metal ions were incorporated in the model generation process and the coordinates of the TSA ligand and 
the Zn
2+ 
ions were copied from the 1T64 structure. Model building was automatically terminated where no 
reference sequence existed for building the template. 
2.3 Docking Calculations  
Nine ligands for the docking study were built in maestro and minimized using Epik and MacroModel. Glide 
was then used to generate the receptor grid using the centroid of the TSA pose from the PfHDAC1 and the 
hHDAC8 model. The Zn
2+
 ion was identified for setting up a metal constraint while the docking calculations 
were carried out in the Glide XP mode. The metal constraint was used for docking and poses were collected 
and ranked using the scoring terms available in Glide.  
3.0 Results And Discussion  
Malaria treatment with new improved drugs is a high priority to addressing the global problem of parasite 
resistance to existing antimalarial drugs
11
 HDAC enzymes in malaria parasites have been tipped to be 
promising target for the development of new antimalarial drugs
12
 but most HDAC inhibitors have relatively 
poor selectivity for P. falciparum compared to normal mammalian cells hence the need to identify inhibitors 
that are more potent and more selective in killing P. falciparum than in killing normal cells. The homology 
model of PfHDAC1 (Ascension number Q9XYC7) was generated using hHDAC8 (PDB 1T64 chain A) and 
HDLP (PDB 1C3R chain A) as templates. 
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Fig. 1: Multiple sequence alignment of Q9XYC7, 1C3R (A) and 1T64 (A) used to                     generate 
PfHDAC 1 model. The structurally conserved regions are indicated by ‘*’. 
The sequence alignment of the templates to the target sequence (Fig. 1) showed that the overall homology of 
the target sequence was greater for hHDAC8 by about 50%. On the bases of this, the HDLP structure was 
used to build the first loop while hHDAC8 was used for modeling the rest of the protein. The average 
sequence homology of the PfHDAC1 with the two homologs was 45%. Loop 1 region of PfHDAC1 
(residues 15-30) and HDLP showed good residue conservation, whereas hHDAC8 has a large insert from 
P22 to C28. There were appreciable numbers of structurally conserved regions.  
 
 
Fig. 2: Homology model of PfHDAC 1 
The homology model (Fig. 2) resulted in a structure with RMSD of <1.0 for the heavy atoms and backbone. 
This may suggest a reasonable 3D model. The Ramachandran plot of the PfHDAC model from Rampage 
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showed a normal distribution of points with Phi (Φ) angles mostly restricted to negative values and Psi (Ψ) 
values clustered in a few distinct regions. It also showed that residue in favored region is 89%, residue in 
allowed region, 7.5% and the residue in outlier region is 3.5%.  
 
3.1 Binding Site 
 
Fig. 
3a: Receptor binding surface of PfHDAC1 model                                 
 
 
Fig. 3b: Ligand interaction diagram of PfHDAC 1 model 
The binding site of the PfHDAC model (Fig. 3a & 3b) is made up of a narrow channel that leads to a deep 
cavity lined by the amino acid residues that are of great importance to the enzymes catalytic machinery. The 
aliphatic chain and dimethyl aniline group of TSA occupies this narrow channel and the terminal 
hydroxamate group enters into the deep cavity and forms several important interactions with the catalytic 
residues ranging from hydrophobic and polar interactions to coordination of the Zn
2+
 metal ion. The metal 
ion is coordinated at five points; three with the side chains of Asp 174, Asp 262, and His 176 while the other 
two are with the carbonyl and hydroxyl oxygen of the ligand’s hydroxamate group as reported by Prasenjit
6
.  
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3.2 Docking of Ligand 
Table 1: Summary of the glide/docking score of PfHDAC 1 and hHDAC8 models 
Ligand Glide/Docking Score 
PfHDAC 1 Model                    hHDAC 8 Model 
SAHA   
 
               -3.348                  -7.728 
Apicidin                  -5.448                  -7.278 
YC – II – 84 
 
              -11.123                       - 
AG – Thai -01 
N
H
O
OH
H
N
O
N
S  
              -11.504                       - 
WR308296  
N
H
O
OH
H
N
O
N
S
H2N
Cl
 
              -11.582                 - 8.397 
WR308291  
N
H
O
OH
H
N
O
N
S
H2N
O
 
              -11.702                 - 6.205 
YC – II – 88 
N
H
O
OH
H
N
O
N
S
H2N  
             - 11.924                      -  
WR308294  
N
H
O
OH
H
N
O
N
S
HO  
             - 12.320                - 7.760 
WR308298   
N
H
O
OH
H
N
O
N
S
H2N
N
HO  
             - 12.934                - 7.400 
Note: The inhibitors are culled from Geoffrey et al.
7
 and Agbor –Enoh et al.
8
 
Table 1 shows the summary of the glide/docking scores of the PfHDAC1 and hHDAC8 models. The docked 
ligands have hydroxamate group as a zinc-binding group (ZBG) that coordinates with the Zn
2+
 ion through 
their carbonyl and hydroxyl oxygen. Table 1 shows that of the nine ligands docked, seven inhibited PfHdac 1 
H
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N
H
OH
O
O
H
N
N
H
OH
O
O
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model (WR308298, WR308294, YC-II-88, WR308291, WR308296, AG-Thai-01, YC-II-84) and three were 
selective for PfHDAC1 (YC-II-88, YC-II-84 and AG-Thai-01) with YC-II-88 being the most selective for 
PfHDAC1 model showing no inhibitory activity for the hHDAC8 model. Experimental results reported by 
Dow et. al.
7
, and Agbor-Enoh et. al.
8
, for the action of these ligands on P.falciparum cell tipped YC-II-88 to 
have the greatest selectivity and more toxic against the parasite than on human cells in vitro and in vivo. This 
theoretical result is in agreement with the experimental results. Comparing the docking result of the 
PfHDAC1 model to that of the hHDAC8 model, it is clear that SAHA and Apicidin are more selective for the 
hHDAC8.  
In terms of structure – activity relationships (SAR), YC-II-88 may have shown greater potency and 
selectivity for the PfHdac1 model due to the substitution of an amine at the Meta position of the terminal 
phenyl ring system while YC-II-84 have reduced potency when compared to YC-II-88 and AG-Thai-01 due 
to the substitution of a non thiazole ring system
7
.  
 
4.0 Conclusion 
 A 3D structure of PfHDAC1 was constructed through homology modeling using Prime (Schrodinger) soft ware. 
The model was then docked with nine ligands seven of which showed selectivity for PfHDAC1 than hHDAC8 
model and three out of the seven showing greater selectivity for the PfHdac model than hHdac 8 model. These 
theoretical results were in agreement with the experimental result reported by Geoffrey et al
7
. and Agbor- Enoh 
et al.
8
 in terms of selectivity. Results of this study after further investigation might be utilized to develop an 
antimalarial drug that incorporates YC-II-88 inhibitor.  
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